Skip to main content

Scynexis Inc

SCYX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001178253

No open-market purchases or sales by Scynexis Inc insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $21.0M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Scynexis Inc changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of SCYX: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders4741−6
Shares14.1M16.3M+2.27M (+16.1%)
Value$54.9M$30.5M−$24.3M (−44.4%)

New holders (7)

Institutions that held Scynexis Inc at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to SCYX in Q2 2022
InstitutionSharesValue% of portfolio
UBS Oconnor LLC506,242$942.0K0.01%
Alyeska Investment Group, L.P.150,000$279.0K0.00%
Jane Street Group, LLC25,745$48.0K0.00%
Walleye Capital LLC23,998$45.0K0.00%
Raymond James & Associates14,763$27.0K0.00%
UBS Group AG2,924$5.00K0.00%
FinTrust Capital Advisors, LLC2,100$5.00K0.00%

Sold out (13)

Institutions that held Scynexis Inc at the end of Q1 2022 and filed for Q2 2022 without it.